The approach behind Amtagvi is a cell therapy conceived by Steve Rosenberg at the National Cancer Institute and has been in development since the late-1980s. The immune system is in constant surveillance and when cancer is detected, lymphocytes (white blood cells) traffic to the tumor to attack and destroy the cancer. The immune cells that enter the tumor are called Tumor Infiltrating Lymphocytes, or TIL, and will include T-cells that recognize distinctive tumor markers (neoantigens) on the cell surface of each person’s cancer. When cancer develops and prevails, the body’s natural TIL can no longer perform their intended function to fight the disease but can be harvested from the tumor and reactivated and reprogrammed as a drug.
About The Author
Iraj Ali has been CEO of Achilles Therapeutics since 2018. Previously he was a managing partner of Syncona Ltd. During his tenure at Syncona he served as an investment partner and board member of Nightstar Therapeutics and Blue Earth Diagnostics. Prior to that he was an associate-principal at McKinsey & Company where he was involved in several major pharmaceutical launches across developed and emerging markets. Ali has a PhD in Biochemistry from Cambridge University.
The approval of the Iovance Biotherapeutics, Inc.'s product is a game changer for researchers and companies developing T-cell-based cancer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
